Product information and disease descriptionProduct descriptionProduct informationPharmacology
Mechanism of action
3 evidence topics · 3 sources
Psilocybin as a prodrug of psilocin, a partial agonist at serotonin receptors
“The psychoactive effects of psilocin are believed to arise due to the partial agonist effects at the 5HT2A receptor.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Psilocin also binds to various other receptor subtypes although the actions of psilocin at other receptors are not fully explored.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Downstream signaling and neuroplasticity
Absence of serotonin release or reuptake inhibition
“Psilocybin and psilocin lack clinically significant inhibitor activity at monoamine reuptake pumps, such as SERT or VMAT-2, thus do not result in substantially increased intrasynaptic serotonin” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Due to minimal intrasynaptic serotonin release, psilocybin’s mechanism of action is unlikely, even in high doses, to result in serotonin toxicity” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote